Objective To investigate the prognostic effect of CD38 in patients with esophageal squamous cell carcinoma patients(ESCC).Methods A retrospective cohort study with 142 ESCC patients was performed.The clinicopathological features and expression of CD38,CD4,CD8,Ki-67,programmed cell death ligand 1(PD-L1)and programmed cell death 1(PD-1)in tumor and immune cells were evaluated.Results Among ESCC patients with lymph node metastasis,the expression of CD38 had a significant association with the overall survival(P=0.037).The median overall survival was 14 months and 38 months among patients with low and high expression of CD38,respectively.The crude and adjusted hazard ratio of high CD38 expression was 0.46(95% CI:0.21-0.98)and 0.32(95% CI:0.13-0.76)respectively.The expression of CD38 had a negative correlation with PD-L1 expressed in tumor cells.Conclusion The high expression of CD38 was associated with a better survival for ESCC with lymph node metastasis.

Objective To investigate the prognostic effect of CD38 in patients with esophageal squamous cell carcinoma patients(ESCC).Methods A retrospective cohort study with 142 ESCC patients was performed.The clinicopathological features and expression of CD38,CD4,CD8,Ki-67,programmed cell death ligand 1(PD-L1)and programmed cell death 1(PD-1)in tumor and immune cells were evaluated.Results Among ESCC patients with lymph node metastasis,the expression of CD38 had a significant association with the overall survival(P=0.037).The median overall survival was 14 months and 38 months among patients with low and high expression of CD38,respectively.The crude and adjusted hazard ratio of high CD38 expression was 0.46(95% CI:0.21-0.98)and 0.32(95% CI:0.13-0.76)respectively.The expression of CD38 had a negative correlation with PD-L1 expressed in tumor cells.Conclusion The high expression of CD38 was associated with a better survival for ESCC with lymph node metastasis.